Camilo Garcia

Camilo Garcia

Auto-generated profile, based on publicly available information

Camilo Garcia

Paris-Saclay University 5 Department of Nuclear Medicine, Gustave Roussy Villejuif, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FDFilippo G. Dall’olio
Filippo G. Dall’olio
AMAurélien Marabelle
Aurélien Marabelle
CCCaroline Caramella
Caroline Caramella
CGCamilo Garcia
Camilo Garcia
MAMihaela Aldea
Mihaela Aldea
BBBenjamin Besse
Benjamin Besse

22 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
FDFilippo Gustavo Dall'Olio
Filippo Gustavo Dall'Olio
WZWael Zrafi
Wael Zrafi
VRVeronique Roelants
Veronique Roelants
Valentina AmbrosiniValentina Ambrosini
Valentina Ambrosini
AFAloÿse Fourquet
Aloÿse Fourquet
BBBenjamin Besse
Benjamin Besse
Purpose: This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell lung cancer (NSCLC) exposed to immune checkpoint blockers (ICB). Experimental Design: In this study, patients with advanced NSCLC and a positive PET scan within 42 days of first-line treatment were enrolled in 11 institutions across four countries. Total MTV (tMTV) was analyzed, with a 42% maximum standardized uptake value threshold. Survival was analyzed according to high tMTV (≥median). Plasma proteomic profile, whole exome, transcriptome, and other analyses were performed on monocentric cohorts to explore its biological correlates. Results: Of the 518 patients included, 167 received ICBs, 257 had chemotherapy plus ICBs, and 94 had chemotherapy. Median tMTV was 99 cm3. Median overall survival (OS) for patients with high tMTV treated with ICBs was 11.4 vs. 29.6 months (P < 0.0012) for those with low tMTV. In patients who received chemotherapy–ICB, tMTV did not correlate with OS (P = 0.099). In patients with programmed death-ligand 1 (PD-L1) ≥1% and high tMTV, chemotherapy–ICB combination was associated with longer OS compared with ICBs alone (20 vs. 11.4 months; P = 0.026), while no survival differences were observed in the low tMTV group. High tMTV correlated (and its detrimental effect seems to be driven) with a specific proteomic profile and increase in genomic instability. Conclusions: Our analysis indicates high tMTV is linked to an increase in systemic inflammation, specific cytokines production, and chromosomal instability. tMTV may serve as one of the biomarkers to select the best upfront strategy in patients with PD-L1–positive advanced NSCLC.

17 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TPThibaut Pierre
Thibaut Pierre
FSFatine Selhane
Fatine Selhane
EZElise Zareski
Elise Zareski
CGCamilo Garcia
Camilo Garcia
KFKarim Fizazi
Karim Fizazi
CBCorinne Balleyguier
Corinne Balleyguier
Ultrasound imaging of the testis represents the standard-of-care initial imaging for the diagnosis of TGCT, whereas computed tomography (CT) plays an integral role in the initial accurate disease staging (organ-confined, regional lymph nodes, or sites of distant metastases), in monitoring the response to therapy in patients who initially present with non-confined disease, in planning surgical approaches for residual masses, in conducting follow-up surveillance and in determining the extent of recurrence in patients who relapse after treatment completion. CT imaging has also an important place in diagnosing complications of treatments. The aims of this article are to review these different roles of CT in primary TGCT and focus on different pitfalls that radiologists need to be aware of.

1 December 2021 in Bulletin du Cancer
Verified
Journal Article
Closed access
DHDana M. Hartl
Dana M. Hartl
JHJulien Hadoux
Julien Hadoux
CGCamilo Garcia
Camilo Garcia
AGAbir Al Ghuzlan
Abir Al Ghuzlan
JGJoanne Guerlain
Joanne Guerlain
LLLivia Lamartina
Livia Lamartina

15 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ADAlexandre Dahan
Alexandre Dahan
AGAbir Al Ghuzlan
Abir Al Ghuzlan
RCRanda Chehab
Randa Chehab
JGJoanne Guerlain
Joanne Guerlain
IBIngrid Breuskin
Ingrid Breuskin
DHDana M. Hartl
Dana M. Hartl
Objective: Thyroid cancer encasing the recurrent nerve is rare, and the decision to resect or preserve the nerve is multifactorial. The objective of this study was to histopathologically analyze resected encased nerves to assess the rate of nerve invasion and risk factors. Materials and Methods: A retrospective study was carried out on consecutive patients with resection of the recurrent nerve for primary or recurrent follicular cell-derived or medullary thyroid carcinoma from 2005 to 2020. Demographics, pathology, locoregional invasion, metastases, recurrences and survival were analyzed. Slides were reviewed blindly by two specialized pathologists (AAG, RC) for diagnosis of invasion deep to the epineurium. Results: Fifty-two patients were included: 25 females; average age, 55 (range 8–87). In total, 87% percent (45/52) were follicular cell-derived with 17/45 (37.8%) aggressive variants; 13% (7/52) were medullary carcinoma. Preoperative vocal fold (VF) paralysis was present in 16/52 (30.7%). Pathologically, the nerve was invaded in 44/52 cases (85%): 82% of follicular cell-derived tumors (37/45), 88% of pediatric cases, and 100% of medullary carcinomas (7/7). Nerve invasion was observed in 11/16 (69%) with preoperative VF paralysis and 33/36 (92%) with normal VF function. Only aggressive histology was correlated with nerve invasion in follicular cell-derived tumors (p = 0.019). Conclusions: The encased nerves were pathologically invaded in 82% of follicular cell-derived tumors and in 100% of medullary carcinomas. Nerve invasion was statistically correlated with aggressive histopathological subtypes and was observed in the absence of VF paralysis in 92% of cases.

23 April 2025 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
AIAlessio Imperiale
Alessio Imperiale
VBValentina Berti
Valentina Berti
RCRoberto Luigi Cazzato
Roberto Luigi Cazzato
DBDarejan Mamulashvili Bessac
Darejan Mamulashvili Bessac
ARAlice Ressault
Alice Ressault
AGAfshin Gangi
Afshin Gangi
Prostate cancer is one of the most common cancers among men, and accurate detection and diagnosis are crucial for effective treatment planning. Diagnostic prostate biopsy plays a pivotal role in the detection and characterization of prostate cancer. Recent advancements in molecular imaging, particularly with Positron Emission Tomography (PET) using radiolabelled Prostate‐Specific Membrane Antigen (PSMA) tracers, have shown significant improvements in enhancing prostate cancer detection. PSMA PET, when combined with magnetic resonance imaging (MRI) in hybrid PET/MRI systems, provides improved sensitivity and specificity, enabling more precise localization of clinically significant prostate cancer (csPCa) lesions. This narrative review explores the evolving role of PET/CT and PET/MRI‐guided prostate biopsy. We examine the integration of PET with MRI for the detection of prostate cancer, highlighting key studies that have demonstrated improved diagnostic outcomes. Additionally, we discuss the current limitations, including the high costs and longer scan times associated with PET/MRI, as well as the challenges in data interpretation. The review also considers emerging technologies, such as promising molecular probes for prostate PET imaging, such as gastrin‐releasing peptide receptor (GRPR) and fibroblast activation protein inhibitor (FAPI). Finally, the present work provides the clinician with a comprehensive yet concise up‐to‐date review of the literature to easily evaluate the possibilities currently offered by hybrid imaging technologies of personalized imaging‐guided biopsy for prostate cancer patients.